He was saying the same thing when DEPO was $8 - $10 and saying how much better DEPO was in relation to SNTS (now SNTS is owns and managing Glu because DEPO inept and DEPO down more on a percentage basis). Time will tell I guess, and better hope Serada does OK or back to $4's or $3's.
Just fools saying DEPO would hit mid-teens on Gralise partner or buyout. What a fumble by DEPO management. PHN not very big indication with vaccines available / Glu indications much larger, so I disagree with rektal.
Here is the label for Gralise. Indicated for PHN. Look at the medication guide, not interchangeable with other Gabapentin products. What doc will really want to take a chance with risks of suicide for gabapentin products and different PK profile for Gralise? Cost will also be a burden on patients with no insurance and for insurance companies paying for non-PHN indications. Things have changed for the worse with regard to coverage and elevated copays.